Literature DB >> 10632674

Osteoblasts and stromal cells isolated from femora in rheumatoid arthritis (RA) and osteoarthritis (OA) patients express IL-11, leukaemia inhibitory factor and oncostatin M.

G Lisignoli1, A Piacentini, S Toneguzzi, F Grassi, B Cocchini, A Ferruzzi, G Gualtieri, A Facchini.   

Abstract

We investigated both in vitro and ex vivo the role of mature osteoblasts (OB) and bone marrow stromal cells (BMSC) in RA and OA by analysing the expression of the following IL-6-type cytokines: IL-11, leukaemia inhibitory factor (LIF), oncostatin M (OSM) and IL-6. OB and BMSC were isolated from femora of RA, OA and post-traumatic (PT) patients, cultured in vitro in the presence or absence of IL-1beta and tumour necrosis factor-alpha (TNF-alpha), and assessed for the production and mRNA expression of IL-6-type cytokines. Trabecular bone biopsies were obtained from the inner portions of femoral heads and used for cytokine in situ immunostaining. Cultured OB and BMSC from different patients constitutively secreted IL-11 and IL-6 but not OSM. LIF was secreted only by BMSC, at very low levels. Interestingly, IL-11 basal production was significantly higher in BMSC than in OB in all three groups tested. IL-1beta and TNF-alpha strongly stimulated IL-6-type cytokine release (except for OSM) by both OB and BMSC. OSM was expressed only at mRNA levels in all groups studied. Cytokine immunostaining on bone biopsies confirmed the data obtained on cultured cells: IL-11, IL-6 and LIF proteins were detected both in mesenchymal (BMSC and OB) and mononuclear cells; OSM was found only in mononuclear cells. These data demonstrate that IL-6-type cytokines are constitutively expressed in the bone compartment in RA, OA and PT patients and can be secreted by bone cells at different stages of differentiation (BMSC and OB). This suggests that these cytokines may be involved in the mechanisms of bone remodelling in OA and RA.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10632674      PMCID: PMC1905501          DOI: 10.1046/j.1365-2249.2000.01114.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  42 in total

1.  Oncostatin-M: a new bone active cytokine that activates osteoblasts and inhibits bone resorption.

Authors:  P R Jay; M Centrella; J Lorenzo; A G Bruce; M C Horowitz
Journal:  Endocrinology       Date:  1996-04       Impact factor: 4.736

2.  Correlation between synovial fluid markers of cartilage and bone turnover and scintigraphic scan abnormalities in osteoarthritis of the knee.

Authors:  M Sharif; E George; P A Dieppe
Journal:  Arthritis Rheum       Date:  1995-01

Review 3.  Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis.

Authors:  S C Manolagas; R L Jilka
Journal:  N Engl J Med       Date:  1995-02-02       Impact factor: 91.245

4.  Production of interleukin-6 in human osteoblasts and human bone marrow stromal cells: evidence that induction by interleukin-1 and tumor necrosis factor-alpha is not regulated by ovarian steroids.

Authors:  L Rifas; J S Kenney; M Marcelli; R Pacifici; S L Cheng; L L Dawson; L V Avioli
Journal:  Endocrinology       Date:  1995-09       Impact factor: 4.736

5.  Interleukin-11: a new cytokine critical for osteoclast development.

Authors:  G Girasole; G Passeri; R L Jilka; S C Manolagas
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

Review 6.  Oncostatin M.

Authors:  A G Bruce; P S Linsley; T M Rose
Journal:  Prog Growth Factor Res       Date:  1992

7.  Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy.

Authors:  P Dieppe; J Cushnaghan; P Young; J Kirwan
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

8.  The effect of leukemia inhibitory factor on bone in vivo.

Authors:  J Cornish; K Callon; A King; S Edgar; I R Reid
Journal:  Endocrinology       Date:  1993-03       Impact factor: 4.736

Review 9.  Cytokines in osteoarthritis: mediators or markers of joint destruction?

Authors:  C I Westacott; M Sharif
Journal:  Semin Arthritis Rheum       Date:  1996-02       Impact factor: 5.532

10.  Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells.

Authors:  T Bellido; N Stahl; T J Farruggella; V Borba; G D Yancopoulos; S C Manolagas
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

View more
  14 in total

1.  Macrophage-derived oncostatin M contributes to human and mouse neurogenic heterotopic ossifications.

Authors:  Frédéric Torossian; Bernadette Guerton; Adrienne Anginot; Kylie A Alexander; Christophe Desterke; Sabrina Soave; Hsu-Wen Tseng; Nassim Arouche; Laetitia Boutin; Irina Kulina; Marjorie Salga; Beulah Jose; Allison R Pettit; Denis Clay; Nathalie Rochet; Erica Vlachos; Guillaume Genet; Charlotte Debaud; Philippe Denormandie; François Genet; Natalie A Sims; Sébastien Banzet; Jean-Pierre Levesque; Jean-Jacques Lataillade; Marie-Caroline Le Bousse-Kerdilès
Journal:  JCI Insight       Date:  2017-11-02

Review 2.  Oncostatin M in the anti-inflammatory response.

Authors:  A F Wahl; P M Wallace
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 3.  Gene expression studies of osteoporosis: implications for microarray research.

Authors:  V Dvornyk; R R Recker; H-W Deng
Journal:  Osteoporos Int       Date:  2003-04-29       Impact factor: 4.507

Review 4.  Osteoimmunology: oncostatin M as a pleiotropic regulator of bone formation and resorption in health and disease.

Authors:  Natalie A Sims; Julian M W Quinn
Journal:  Bonekey Rep       Date:  2014-05-14

5.  Human osteoclasts express different CXC chemokines depending on cell culture substrate: molecular and immunocytochemical evidence of high levels of CXCL10 and CXCL12.

Authors:  Francesco Grassi; Anna Piacentini; Sandra Cristino; Stefania Toneguzzi; Carola Cavallo; Andrea Facchini; Gina Lisignoli
Journal:  Histochem Cell Biol       Date:  2003-11-05       Impact factor: 4.304

Review 6.  Pathologic thrombopoiesis of rheumatoid arthritis.

Authors:  Ihsan Ertenli; Sedat Kiraz; M Akif Oztürk; Ibrahim c Haznedaroğlu; Ismail Celik; Meral Calgüneri
Journal:  Rheumatol Int       Date:  2003-02-11       Impact factor: 2.631

7.  Anticytokine therapy for osteoarthritis: evidence to date.

Authors:  Charles J Malemud
Journal:  Drugs Aging       Date:  2010-02-01       Impact factor: 3.923

8.  TLR signaling that induces weak inflammatory response and SHIP1 enhances osteogenic functions.

Authors:  Manoj Muthukuru; Richard P Darveau
Journal:  Bone Res       Date:  2014-11-11       Impact factor: 13.567

9.  CCN1 induces oncostatin M production in osteoblasts via integrin-dependent signal pathways.

Authors:  Cheng-Yu Chen; Chen-Ming Su; Yuan-Li Huang; Chun-Hao Tsai; Lih-Jyh Fuh; Chih-Hsin Tang
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

Review 10.  Advanced glycation end products play adverse proinflammatory activities in osteoporosis.

Authors:  Roberta Sanguineti; Alessandra Puddu; François Mach; Fabrizio Montecucco; Giorgio Luciano Viviani
Journal:  Mediators Inflamm       Date:  2014-03-20       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.